We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Health Care Provider-mediated, Remote Coaching System Through the PDA-type Glucometer and the Internet on Diabetes Management

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01041144
First Posted: December 31, 2009
Last Update Posted: December 31, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Ministry for Health Welfare and Family Affairs
Information provided by:
The Catholic University of Korea
  Purpose

The purpose of this study is to investigate the effectiveness of the new diabetes care delivery system applied to preexisting public health care resources through advanced information technologies such as PDA-type glucometer and the Internet on the glycemic control of type 2 diabetes patients lived in isolated rural area.

The investigators conducted a prospective, randomized, controlled trial in patients with type 2 diabetes for 12 weeks. The intervention group was treated with the new health care delivery system, where diabetes center provided specialized management, mediated by nurse of primary health care posts using the Internet and the PDA-type glucometer, while the control group with conventional health care. HbA1c, fasting plasma glucose and lipids levels were measured at baseline and follow-up.


Condition Intervention
Type 2 Diabetes Lifestyle Intervention Glucose Control Internet Communication Behavioral: lifestyle counseling

Study Type: Interventional
Study Design: Primary Purpose: Supportive Care

Resource links provided by NLM:


Further study details as provided by The Catholic University of Korea:

Primary Outcome Measures:
  • HbA1c

Secondary Outcome Measures:
  • PP2hr Lipid profile

Estimated Enrollment: 115
Arms Assigned Interventions
Experimental: Lifestyle counseling Behavioral: lifestyle counseling
supporting diabetes patients using Internet communication

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Type 2 diabetes patients
  • Aged ≥ 40 years
  • Baseline HbA1c of 7.0 to 11.0 % who had been already followed up for more than 6 months in the health care post

Exclusion Criteria:

  • Participants with diagnosed or suspected disease of the liver, pancreas, endocrine organs, or kidney
  • Ischemic heart disease or cerebrovascular disease or a history of such disease
  • A creatinine level > 0.133 mmol/L
  • Treatment with an intensified insulin regimens and those unable .
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01041144


Locations
Korea, Republic of
Seoul St. Mary's Hospital
Seoul, Korea, Republic of, 137-041
Sponsors and Collaborators
The Catholic University of Korea
Ministry for Health Welfare and Family Affairs
Investigators
Principal Investigator: Kun-Ho Yoon, Ph.D. Catholic Medical College
  More Information

ClinicalTrials.gov Identifier: NCT01041144     History of Changes
Other Study ID Numbers: Seoul R&D Project
First Submitted: December 30, 2009
First Posted: December 31, 2009
Last Update Posted: December 31, 2009
Last Verified: June 2005

Keywords provided by The Catholic University of Korea:
Diabetes
PDA
Internet
HbA1c